Alpha interferon and hepatitis B and C. An integrated approach using practice guidelines.
Utilizing the techniques of total quality management, a team designed a clinical guideline for the use of alpha interferon as a treatment for patients with chronic hepatitis. The team included TEMINEX staff, a primary care physician, the plan's internal gastroenterologist, and its university-based consultant gastroenterologists. A synopsis of the available published research data and clinical opinion (a draft TEMINEX report) was used to focus discussions. The final TEMINEX report represented consensus on patient selection criteria and treatment regimens. All members of the team agreed to a review and approval process. Although quantitative data concerning the effects of guideline implementation are not yet available, it appears that the concerns of all members of the team have been satisfied. Patient selection criteria supported by the results of well-designed research are in place. Appropriate candidates for alpha-interferon therapy receive expedited treatment and the plan's internal monitoring processes are more efficient. Primary care physicians and consultant gastroenterologists feel that they made positive contributions both to the quality of care and to the consensus development process.
Reinhard
J
J
TEMINEX Project, Health Care Plan, Buffalo, NY 14202.
Flynn
K
K
Katz
L
L
Mahl
T
T
Corasanti
J
J
D006279:Health Maintenance Organizations / Q000458:organization & administration / Q000592:standards*; D006509:Hepatitis B / Q000188:drug therapy* / Q000517:prevention & control*; D006526:Hepatitis C / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D013673:Technology Assessment, Biomedical / Q000458:organization & administration; D017749:Total Quality Management / Q000458:organization & administration*; D014481:United States